Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of a Reduced-toxicity Myeloablative Conditioning Regimen in Pediatric Patients
NCT01572181Phase 2Completed
- Sponsor
- CHU de Nantes
- Start
- Apr 2012
- Primary completion
- Oct 2017
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fludarabine, busulfan and antithymocyte globulin rabbit in hematologic malignancy, sponsored by CHU de Nantes. Primary endpoint: Transplant-related mortality at 12 months. Started Apr 2012; status: completed.
02
Drugs
fludarabinebusulfanantithymocyte globulin rabbit
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT01572181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01572181.